Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 1.57 is 68% above its 3-year average of 0.93, near the high end of its 3-year range (0.57–1.57).
As of the fiscal period ended Wednesday, December 31, 2025. 63.90% above its 12-month average of 0.96.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2025 (2025-12-31): 1.57.
DEBT TO EQUITY RATIO
1.57
DEBT TO EQUITY RATIO AVG TTM
0.96
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+63.90%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.17
median of 340 covered companies
CURRENT VS SECTOR MEDIAN
+824.75%
vs the sector median at left
Basel Medical Group Ltd Ordinary Shares
Market Cap
$4.96M
Debt to Equity Ratio
1.57
TTM Avg
0.96
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.79M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$5.36M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.03
Market Cap
$4.46M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$4.42M
Debt to Equity Ratio
0.90
TTM Avg
0.35
3Y Avg
0.23
5Y Avg
0.29
Market Cap
$4.41M
Debt to Equity Ratio
0.11
TTM Avg
0.30
3Y Avg
4.92
5Y Avg
3.36
Market Cap
$4.32M
Debt to Equity Ratio
0.18
TTM Avg
0.73
3Y Avg
0.52
5Y Avg
0.35
Market Cap
$5.63M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Basel Medical Group Ltd Ordinary Shares (BMGL) | $4.96M | 1.57 | 0.96 | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.85M | 0.00 | 0.00 | 0.00 | 0.92 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | 0.00 | 0.00 | 0.02 | 0.02 |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | 0.00 | 0.00 | 0.00 | 0.03 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | 0.00 | 0.00 | 0.00 | 0.00 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | 0.90 | 0.35 | 0.23 | 0.29 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | 0.11 | 0.30 | 4.92 | 3.36 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | 0.18 | 0.73 | 0.52 | 0.35 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | 0.00 | 0.00 | 0.00 | 0.00 |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | 0.70 | 0.62 | 0.55 | 2.94 |
Debt/Equity
1.57
Current Ratio
1.88
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 1.57 |
| 2025-06-30 | 0.70 |
| 2024-12-31 | 0.60 |
| 2024-06-30 | 0.57 |
| 2023-12-31 | 0.84 |
| 2023-06-30 | 1.31 |
